In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

OriGene's Series B brings in $16mm

Executive Summary

OriGene Technologies Inc. (genomics- and proteomics-based research tools for life sciences companies) raised $16mm through its Series B round. IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO led and were joined by existing investors Morningside Venture Investments and President International Development Corp. OriGene will use the proceeds to continue work on its TrueMAB collection of monoclonal antibodies.
Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies